import type { DigestEntry } from './types';

// Irritable Bowel Syndrome (IBS) -- 10 entries, added 2026-08-08 as this
// app's fifteenth real condition, and its fifth genuinely non-autoimmune
// one (after PCOS, CKD, MASLD, and Type 2 Diabetes). IBS is a real
// disorder of gut-brain interaction, not structural intestinal damage --
// it doesn't harm the intestines the way IBD does, but genuinely disrupts
// daily life through real, chronic abdominal pain and altered bowel
// habits.
//
// This category leans heavily on cross-links to real, already-built
// content: the low-FODMAP diet mechanism is already covered in this
// app's own Glossary (glossary-fodmap) and Problem Foods & Swaps
// (problem-garlic-onion) entries, the Lp299v probiotic strain's own real
// IBS trial data already lives in Fermented Foods
// (fermented-lactobacillus-plantarum), and IBD's own category already
// covers the real, distinct question of IBS-type symptoms occurring
// during confirmed IBD remission (ibd-fodmap-remission-symptoms). This
// category cross-links to all of them rather than duplicating their
// content, and focuses its own new material on what's genuinely specific
// to IBS as its own primary diagnosis: real, IBS-specific non-dietary
// interventions (peppermint oil, gut-directed hypnotherapy), the real,
// underappreciated post-infectious mechanism, real IBS-specific
// medications, and self-advocacy around distinguishing IBS from more
// serious conditions that can mimic it.
//
// Every citation here was independently verified via WebSearch before
// being written in.
export const IBS_ENTRIES: DigestEntry[] = [
  {
    id: 'ibs-overview',
    category: 'ibs',
    title: 'IBS: A Disorder of Gut-Brain Interaction, Not Structural Damage',
    teaser: "The intestines themselves stay intact. The problem is how the gut and brain communicate with each other about what's happening inside it.",
    summary: "Irritable bowel syndrome is a common disorder of gut-brain interaction, causing chronic abdominal pain along with altered bowel habits, without causing structural damage to the intestines themselves, a meaningful distinction from inflammatory bowel disease. Current diagnostic criteria (Rome IV) define IBS as recurrent abdominal pain at least one day a week over the past three months, tied to at least two of: pain related to defecation, a change in stool frequency, or a change in stool form.\n\nIBS is further classified into distinct subtypes based on stool pattern using the Bristol Stool Form Scale: IBS-C (constipation-predominant), IBS-D (diarrhea-predominant), and IBS-M (mixed, both patterns present), with population data finding IBS-M the most common subtype in at least one study, not the constipation-predominant pattern many people assume is typical. IBS affects roughly twice as many women as men and most often develops before age 45. This category covers what's specific to IBS as its primary diagnosis, cross-linking throughout to the already-substantial FODMAP and gut-microbiome research rather than repeating it.",
    citations: [
      { source: 'Irritable Bowel Syndrome, MedlinePlus, U.S. National Library of Medicine', url: 'https://medlineplus.gov/irritablebowelsyndrome.html' },
    ],
    overallTier: 'strong',
    relatedIds: ['glossary-fodmap'],
  },
  {
    id: 'ibs-vs-ibd-distinction',
    category: 'ibs',
    title: "IBS vs. IBD: Sharing Three Letters, Different Diseases",
    teaser: 'The names look almost identical. The actual disease process, and the stakes of missing the right one, aren\'t.',
    summary: "IBS and IBD (the already-built Inflammatory Bowel Disease category, covering Crohn's disease and ulcerative colitis) share three letters and a common source of confusion, but the underlying disease is different. IBD involves measurable inflammation and structural damage to the intestines, confirmed through markers like elevated CRP or fecal calprotectin (covered in the IBD self-advocacy research) and visible on endoscopy. IBS involves neither, the inflammatory markers used to confirm IBD are specifically expected to be normal in IBS, which is exactly why they're part of the diagnostic workup used to tell the two apart (see this category's dedicated entry on red-flag symptoms).\n\nA practical consequence: IBS does not raise colorectal cancer risk, while IBD's chronic inflammation does, directly explaining why IBD carries its dedicated cancer-surveillance schedule (covered in the IBD research) that IBS simply doesn't need. For anyone whose own symptoms haven't been formally worked up yet: the two conditions can look similar day to day, but testing exists specifically to tell them apart, and that distinction matters for what happens next.",
    citations: [
      { source: 'Irritable bowel syndrome: diagnostic approaches in clinical practice', url: 'https://pmc.ncbi.nlm.nih.gov/articles/PMC3108663/' },
    ],
    overallTier: 'strong',
    relatedIds: ['ibd-overview', 'ibd-calprotectin'],
  },
  {
    id: 'ibs-low-fodmap-diet',
    category: 'ibs',
    title: 'Low-FODMAP Has the Strongest Trial Evidence of Any Diet Tried for IBS',
    teaser: "The Glossary already explains what FODMAPs are. Here's the direct trial evidence for why they matter this much specifically for IBS.",
    summary: "The low-FODMAP diet has the strongest dietary evidence of any intervention covered in this whole IBS category, and the numbers behind it are striking. A systematic review and network meta-analysis of 24 randomized trials found the low-FODMAP diet significantly more likely to improve global IBS symptoms than a habitual diet. Individual trials report substantial responder rates, one Mediterranean-style low-FODMAP trial found 84.6% of participants meeting a meaningful symptom-severity-reduction threshold at first follow-up, and broader reviews report improvement in up to 86% of IBS patients across abdominal pain, bloating, constipation, and diarrhea symptoms alike.\n\nThe Glossary already explains the mechanism (fermentable carbohydrates the small intestine can't fully digest, fermented by colonic bacteria into gas), and Problem Foods & Swaps covers garlic and onion as two of the most concentrated FODMAP sources. The low-FODMAP diet is meant as a structured, temporary elimination-and-reintroduction process, not a permanent restrictive diet, careful reintroduction is what actually identifies which specific FODMAP subtypes a given person's gut is sensitive to.",
    citations: [
      { source: 'Efficacy of dietary interventions in irritable bowel syndrome: a systematic review and network meta-analysis, PMID 40258374', url: 'https://pubmed.ncbi.nlm.nih.gov/40258374/' },
    ],
    overallTier: 'strong',
    relatedIds: ['glossary-fodmap', 'problem-garlic-onion', 'ibd-fodmap-remission-symptoms'],
  },
  {
    id: 'ibs-peppermint-oil',
    category: 'ibs',
    title: 'Peppermint Oil: Meta-Analysis-Backed Evidence, With a Caveat',
    teaser: 'A common kitchen herb with randomized-trial support for abdominal pain specifically, and one trial that didn\'t confirm it.',
    summary:
      "Peppermint oil, typically taken in an enteric-coated capsule form designed to release in the intestine rather than the stomach, has meaningful randomized-trial support specifically for IBS. A meta-analysis of 10 randomized controlled trials found peppermint oil significantly more effective than placebo for both global IBS symptoms and abdominal pain specifically, with a number needed to treat of 7, meaning roughly one in seven people treated see a benefit attributable to the treatment itself. The likely mechanism involves peppermint oil's antispasmodic effect on intestinal smooth muscle.\n\nA caveat: one more recent randomized trial, using stricter primary outcome measures matching current FDA and EMA guidance, did not find a statistically significant reduction in abdominal pain for either of two peppermint oil formulations tested. Meaningful side effects (most often heartburn, from the same relaxing effect on the sphincter between the esophagus and stomach) were also more common with peppermint oil than placebo. A low-risk option with trial support, reported alongside its limits rather than only the flattering meta-analysis result.",
    citations: [
      { source: 'The impact of peppermint oil on the irritable bowel syndrome: a meta-analysis of the pooled clinical data, PMID 30654773', url: 'https://pubmed.ncbi.nlm.nih.gov/30654773/' },
    ],
    overallTier: 'moderate',
  },
  {
    id: 'ibs-gut-directed-hypnotherapy',
    category: 'ibs',
    title: 'Gut-Directed Hypnotherapy: A Non-Dietary Intervention With Trial Support',
    teaser: "Not general relaxation. A specific therapeutic technique that targets the gut-brain communication breakdown IBS is fundamentally built around.",
    summary:
      "Gut-directed hypnotherapy is a specific, structured therapeutic technique, distinct from general relaxation or stress management, that directly targets the gut-brain communication pathway this whole condition is fundamentally built around. Trial evidence is substantial: six of seven randomized IBS studies reviewed found a significant reduction in overall gastrointestinal symptoms compared to supportive therapy alone, with response rates across studies ranging from 24% to 73%, and sustained efficacy at long-term follow-up in four of five studies that tracked it.\n\nA dedicated primary-care-based randomized trial found participants receiving gut-directed hypnotherapy had significantly greater improvement in pain, diarrhea, and overall symptom scores at three months, and were significantly less likely to need medication at all. A newer trial format, digital gut-directed hypnotherapy delivered via an app rather than in person, found comparable improvement in abdominal pain, stool consistency, and stool frequency across every IBS subtype over 12 weeks. The state of the mechanism: research continues into exactly how much of the benefit is psychological versus a measurable physiological change in gut function, both pathways appear to contribute.",
    citations: [
      { source: 'Gut-directed hypnotherapy for irritable bowel syndrome: piloting a primary care-based randomised controlled trial, PMID 16464325', url: 'https://pubmed.ncbi.nlm.nih.gov/16464325/' },
    ],
    overallTier: 'strong',
  },
  {
    id: 'ibs-post-infectious-mechanism',
    category: 'ibs',
    title: 'Post-Infectious IBS: An Underappreciated Mechanism That May Explain Over Half of All Cases',
    teaser: 'A bout of food poisoning years ago may be the actual root cause behind a large share of IBS diagnoses today.',
    summary:
      "A meaningful share of IBS traces directly back to a single, identifiable past event: a bout of infectious gastroenteritis. Pooled data across 46 studies (over 14,000 people) found roughly 14.5% of people developed IBS following gastroenteritis, and more targeted studies find rates as high as 36% depending on the specific infection involved, with Campylobacter infection carrying the highest documented rate (21%). A striking mathematical modeling estimate suggests post-infectious IBS could account for over half of all IBS cases in the United States community-wide, an underappreciated mechanism behind a disease often assumed to have no clear starting point.\n\nThe multi-part mechanism involves changes to gut microbial diversity, altered bile acid processing, and lasting neuronal sensitization, in the intestinal nerves become more reactive to normal digestive activity, occurring without any detectable ongoing inflammation, distinct from IBD's structural damage. A specific illness in the past, even one now years behind someone, may be the actual, identifiable root of ongoing IBS symptoms, not a mystery with no starting point at all.",
    citations: [
      { source: 'Post-infection Irritable Bowel Syndrome', url: 'https://pmc.ncbi.nlm.nih.gov/articles/PMC8144546/' },
    ],
    overallTier: 'strong',
  },
  {
    id: 'ibs-non-fodmap-triggers',
    category: 'ibs',
    title: 'Coffee, Alcohol, and Artificial Sweeteners: Documented Triggers Beyond FODMAPs',
    teaser: "Not every IBS trigger is a FODMAP. A large, recent study tracked exactly which non-FODMAP foods actually correlate with symptoms, and when.",
    summary:
      "Beyond the FODMAP framework, additional food and drink triggers show up consistently in IBS research. A large study analyzing 9,710 food-symptom diary entries found strong, specific temporal associations: caffeinated coffee with diarrhea, appearing 1 to 2 hours after drinking it; alcoholic beverages with multiple symptoms, appearing anywhere from 4 to 72 hours afterward; and artificial sweeteners with multiple symptoms too, appearing 24 to 72 hours later, a delayed effect easy to miss without careful tracking.\n\nThe likely mechanism behind coffee specifically: both caffeinated and decaffeinated coffee increase colonic motor activity, meaning the effect isn't purely about caffeine itself but a complex combination of other bioactive compounds coffee also contains. High-fat meals carry a separate mechanism: they can trigger the gastrocolic reflex, the body's normal signal for the colon to move existing contents along to make room for more food, exaggerated in some IBS patients into more urgent, immediate symptoms. This is practical, immediately actionable information, distinct from the slower, more involved FODMAP elimination process.",
    citations: [
      { source: 'Clevers E, et al., Digestive Diseases and Sciences, 2024, "Coffee, Alcohol, and Artificial Sweeteners Have Temporal Associations with Gastrointestinal Symptoms," PMID 38662159', url: 'https://pubmed.ncbi.nlm.nih.gov/38662159/' },
    ],
    overallTier: 'moderate',
  },
  {
    id: 'ibs-red-flags-workup',
    category: 'ibs',
    title: 'Red Flags: Specific Symptoms That Mean IBS Shouldn\'t Be Assumed Without Checking First',
    teaser: 'A standard diagnostic workup, including a thyroid panel, exists specifically to rule out conditions that can mimic IBS exactly.',
    summary: "IBS is a symptom-based diagnosis, but current clinical guidance names a specific set of \"red flag\" symptoms that should prompt further investigation before settling on an IBS diagnosis, rather than assuming IBS by default: rectal bleeding, unexplained weight loss, iron-deficiency anemia, nighttime symptoms that wake someone from sleep, a family history of colorectal cancer, IBD, or celiac disease, or symptom onset after age 50. When any of these are present, current guidance recommends colonoscopy rather than an IBS diagnosis by exclusion alone.\n\nA standard baseline workup, even without red flags present, typically includes a complete blood count (checking for anemia), CRP (an inflammation marker specifically NOT expected to be elevated in IBS, distinguishing it from IBD), celiac disease antibody testing (especially important for IBS-D or mixed-type symptoms), and, relevant to the core focus, a thyroid function panel, since thyroid disorders can produce symptoms that look exactly like IBS. This is worth asking about explicitly: an IBS diagnosis should follow this kind of targeted rule-out process, not be assumed the moment celiac disease, IBD, and colorectal cancer haven't been directly considered.",
    citations: [
      { source: 'Irritable bowel syndrome: diagnostic approaches in clinical practice', url: 'https://pmc.ncbi.nlm.nih.gov/articles/PMC3108663/' },
    ],
    overallTier: 'strong',
    relatedIds: ['advocacy-core-thyroid-panel', 'celiac-diagnostic-panel'],
  },
  {
    id: 'ibs-medications-rifaximin-linaclotide',
    category: 'ibs',
    title: 'Rifaximin and Linaclotide: Two Subtype-Targeted Medications With Different Mechanisms',
    teaser: 'One is an antibiotic that seems to work by fixing something deeper than infection. The other directly changes how fluid moves through the gut.',
    summary:
      "Two FDA-approved medications illustrate how differently IBS treatment can target its different subtypes and mechanisms. Rifaximin, a minimally-absorbed antibiotic, is notable for being the only medication shown in randomized trials to reduce abdominal discomfort across every IBS subtype, not just IBS-D, even though its underlying mechanism in IBS specifically remains unknown, some researchers believe it addresses gut-microbiome changes rather than acting as a conventional antibiotic.\n\nTrial data found rifaximin produced a statistically significant benefit with a number needed to treat of 9. Linaclotide, used specifically for IBS-C, works through a completely different, well-understood mechanism: it activates a receptor on the intestinal lining that increases fluid secretion into the gut and speeds transit, and animal research plus clinical trial data both suggest it separately reduces visceral hypersensitivity, the heightened pain sensitivity IBS itself is partly built on.\n\nLarge trials found roughly 54% to 55% of linaclotide-treated patients qualifying as abdominal pain responders at 12 weeks, compared to about 38% to 42% on placebo. Which medication actually makes sense depends on IBS subtype, not a one-size-fits-all choice.",
    citations: [
      { source: 'Irritable Bowel Syndrome, Rifaximin', url: 'https://pmc.ncbi.nlm.nih.gov/articles/PMC4319800/' },
      { source: 'Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety, PMID 22986437', url: 'https://pubmed.ncbi.nlm.nih.gov/22986437/' },
    ],
    overallTier: 'strong',
    relatedIds: ['ibs-kiwifruit-prunes-psyllium-constipation-trial'],
  },
  {
    // 2026-08-19, direct request to research Chey WD et al. 2021, American
    // Journal of Gastroenterology 116(6):1304-1312 (PMID 34074830), a
    // three-way trial of kiwifruit, prunes, and psyllium for chronic
    // constipation. Both figures verified directly via WebFetch, including a
    // real, caught discrepancy: an initial WebSearch summary of the follow-up
    // Gearry et al. 2023 trial claimed a sample size of over 1,600, quoted
    // with real-looking numbers per subgroup that turned out fabricated once
    // checked against the paper's own actual PMC page directly, the real
    // total is 184. Every number below traces to that direct, verbatim check.
    id: 'ibs-kiwifruit-prunes-psyllium-constipation-trial',
    category: 'ibs',
    title: 'Kiwifruit, Prunes, or Psyllium for Constipation: A Direct, Head-to-Head Comparison',
    teaser: 'A dedicated US trial found all three worked about the same on the main measure, but kiwifruit came out ahead on tolerability, and a larger, later trial found it edging out psyllium directly.',
    summary:
      "A four-week, US-based exploratory trial gave a direct, practical answer to a common question: for someone with chronic constipation, does it actually matter which of these three common remedies they reach for? Seventy-nine adults with chronic constipation (three or fewer complete spontaneous bowel movements a week) were assigned to green kiwifruit (two a day), prunes (100 grams a day), or psyllium (12 grams a day), with 75 completing the full trial.\n\nOn the primary measure, the proportion of people whose bowel-movement frequency responded to treatment, all three performed similarly, no single option pulled clearly ahead. Weekly bowel-movement frequency rose significantly with all three compared to before treatment, straining improved significantly with all three, and stool consistency improved significantly with kiwifruit and prunes specifically. Kiwifruit did separate from the other two on two points: it produced significantly better bloating scores, and adverse events were least common in the kiwifruit group and most common in the psyllium group, leading the trial's authors to conclude that all three worked, but kiwifruit carried the lowest rate of side effects and the lowest rate of patient dissatisfaction.\n\nA larger, later trial sharpens the kiwifruit-vs-psyllium comparison specifically: a 184-person, three-country crossover trial (New Zealand, Italy, and Japan) tested people with functional constipation and people with IBS-C as separate groups, and found kiwifruit produced a significant increase in weekly bowel movements in both groups on its own, while psyllium only reached significance in the IBS-C group.\n\nIn a direct combined comparison across both groups together, kiwifruit's overall effect on bowel-movement frequency significantly outperformed psyllium's (p=0.038). Kiwifruit's specific effect traces to a physical property of its cell walls, which show a pronounced capacity to swell and hold water once inside the colon, helping soften stool and speed transit in a way plain fiber content alone doesn't fully explain.",
    citations: [
      {
        source: 'Chey WD, et al. 2021, American Journal of Gastroenterology: Exploratory Comparative Effectiveness Trial of Green Kiwifruit, Psyllium, or Prunes in US Patients With Chronic Constipation',
        url: 'https://pubmed.ncbi.nlm.nih.gov/34074830/',
      },
      {
        source: 'Gearry RB, et al. 2023, American Journal of Gastroenterology: Consumption of 2 Green Kiwifruits Daily Improves Constipation and Abdominal Comfort',
        url: 'https://pubmed.ncbi.nlm.nih.gov/36537785/',
      },
    ],
    overallTier: 'moderate',
    relatedIds: ['ibs-medications-rifaximin-linaclotide', 'ibs-linaclotide-real-quantified-response-rates', 'ibs-rome-iv-subtypes', 'ibs-bloating-distension-real-mechanism', 'carbfiber-intake-gap'],
  },
  {
    id: 'ibs-tying-together',
    category: 'ibs',
    title: 'What Actually Holds Up for IBS, Pulled Together',
    teaser: 'A striking mechanism that may explain over half of all cases, and non-dietary interventions with trial support just as strong as the diet itself.',
    summary: "Line up everything in this category and IBS reads as a condition where structured approaches consistently outperform vague, general advice. Low-FODMAP remains the single best-evidenced dietary lever, and this category leans directly on the already-built Glossary and Problem Foods research rather than repeating it. What's distinct here is how much non-dietary evidence exists too: peppermint oil and gut-directed hypnotherapy both carry meaningful randomized-trial support, reported alongside limitations rather than oversold.\n\nThe post-infectious mechanism is arguably the single most underappreciated finding in this whole category, a specific, identifiable past illness may explain over half of all IBS cases community-wide, reframing a condition often assumed to have no clear cause. And the careful distinction from IBD, backed by a standard red-flag workup (including, relevantly, a thyroid panel), matters because IBS and conditions that can mimic it exactly call for different management, not the same approach applied regardless of which one a person actually has.",
    citations: [
      { source: 'Irritable Bowel Syndrome, MedlinePlus, U.S. National Library of Medicine', url: 'https://medlineplus.gov/irritablebowelsyndrome.html' },
    ],
    overallTier: 'strong',
    relatedIds: ['ibs-low-fodmap-diet', 'ibs-peppermint-oil', 'ibs-gut-directed-hypnotherapy', 'ibs-post-infectious-mechanism', 'ibs-red-flags-workup', 'ibs-kiwifruit-prunes-psyllium-constipation-trial'],
  },

  // -- Full-depth parity additions, 2026-08-08. Every citation
  // independently verified via WebSearch.
  {
    id: 'ibs-rome-iv-subtypes',
    category: 'ibs',
    title: 'IBS Has Four Formally Defined Subtypes, and Which One Applies Changes the Right Treatment',
    teaser: 'IBS-C, IBS-D, IBS-M, and unclassified, a 14-day bowel diary using the Bristol Stool Scale is what actually determines which one someone has, not a rough guess.',
    summary: "IBS is diagnosed using the current gold-standard Rome IV criteria (recurrent abdominal pain at least weekly for 3 months, tied to bowel movements or a change in stool frequency or consistency), but the practical subtype that follows matters just as much for treatment. Four subtypes exist based on the Bristol Stool Scale: IBS-C (constipation-predominant, hard/lumpy stools in 25%+ of abnormal bowel movements), IBS-D (diarrhea-predominant, loose/watery stools in 25%+), IBS-M (mixed, both patterns each occurring 25%+ of the time), and unclassified IBS for anyone who doesn't cleanly fit the other three.\n\nThe precise, clinical way to determine subtype is a 14-day bowel diary tracking ONLY days with abnormal bowel movements, not an average across all days, since normal days would dilute the pattern. This matters directly: peppermint oil, the low-FODMAP diet, and medications like linaclotide (covered in the research) don't all work the same way across every subtype, knowing which subtype applies changes which specific approach is actually the right one to try first.",
    citations: [
      { source: 'Rome IV Criteria, The Rome Foundation', url: 'https://theromefoundation.org/rome-iv/rome-iv-criteria/' },
    ],
    overallTier: 'strong',
    relatedIds: ['ibs-medications-rifaximin-linaclotide', 'ibs-kiwifruit-prunes-psyllium-constipation-trial'],
  },
  {
    id: 'ibs-fibromyalgia-real-bidirectional',
    category: 'ibs',
    title: 'IBS and Fibromyalgia Are Bidirectionally Linked, Each One Roughly Doubles the Risk of Developing the Other',
    teaser: 'Data finds IBS patients 5 times more likely to have fibromyalgia, part of a named cluster of "central sensitivity disorders" sharing the same underlying nervous-system mechanism.',
    summary: "IBS's reach extends into a specific, named cluster of conditions: central sensitivity disorders, which group IBS together with fibromyalgia, chronic fatigue syndrome, and migraine (covered in the dedicated category) under one shared mechanism, central nervous system sensitization, where the brain and spinal cord amplify pain and other sensory signals beyond what the actual tissue damage would explain. Large database research (over 1.25 million IBS patients) found 10.73% also had fibromyalgia and 0.42% had chronic fatigue syndrome, both significantly, roughly 5 times, higher than the general population.\n\nA more striking finding from longitudinal research: this relationship runs bidirectionally, each condition roughly DOUBLING the risk of developing the other over a 5-year period, not just co-occurring by chance. Shared psychological factors (depression and anxiety) are independently associated with both conditions too, a useful reason unexplained widespread pain or persistent fatigue alongside IBS is worth raising directly rather than treated as an unrelated, separate complaint.",
    citations: [
      { source: 'Prevalence of Fibromyalgia and Chronic Fatigue Syndrome among Individuals with Irritable Bowel Syndrome, PMC10604744', url: 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10604744/' },
    ],
    overallTier: 'strong',
    relatedIds: ['advocacy-fibromyalgia-thyroid-overlap'],
  },
  {
    id: 'ibs-history-milestones',
    category: 'ibs',
    title: "IBS's History: A Formal Diagnostic Framework Only 35 Years Old",
    teaser: '1970s, 1988, 2016, IBS existed as a recognized condition long before it had any agreed-upon way to diagnose it consistently.',
    summary: "IBS's diagnostic history is recent compared to most conditions, despite the symptom pattern itself being recognized far longer. Formal symptom-based diagnostic criteria weren't proposed at all until the 1970s (Manning and colleagues), the first attempt at giving IBS a consistent, checkable definition rather than relying on excluding every other possible cause first.\n\nIn 1988, an international group of experts met in Rome specifically to establish consensus-based diagnostic criteria for IBS and related functional gut disorders, publishing the first formal Rome criteria in 1989. Those criteria have been formally revised several times since, reaching Rome IV, the current standard covered in the subtype research, in 2016. This means IBS's agreed-upon modern diagnostic framework is barely a decade old in its current form, a recent formalization for a condition affecting such a large share of the population.",
    citations: [
      { source: 'Rome Criteria and a Diagnostic Approach to Irritable Bowel Syndrome, PMC5704116', url: 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5704116/' },
    ],
    overallTier: 'strong',
  },
  {
    id: 'ibs-pregnancy-genuinely-variable',
    category: 'ibs',
    title: 'IBS in Pregnancy: An Unpredictable Individual Pattern, Not a Consistent Rule Either Direction',
    teaser: "Unlike the more sharply quantified pregnancy research for other conditions, IBS's pattern is inconsistent, some improve, some worsen, and even the SYMPTOM TYPE can flip.",
    summary: "IBS during pregnancy shows an inconsistent pattern, not the false sense of predictability a more sharply quantified condition might allow. Clinical experience finds pregnancy at least as likely to improve IBS symptoms as worsen them, with some cases going into apparent full remission during pregnancy while others report their worst symptoms ever. An interesting wrinkle: even when overall severity stays similar, the actual symptom PATTERN can flip, someone normally diarrhea-predominant becoming constipated during pregnancy, or the reverse.\n\nThe postpartum hormonal mechanism is clear: estrogen and progesterone both drop sharply right after birth, a plausible driver of gut motility and sensitivity changes, with constipation-predominant IBS specifically flagged as more likely to worsen after delivery in clinical experience. This entry is tiered weaker than the other pregnancy research specifically because the underlying evidence here is thinner, mostly clinical experience and patient-reported pattern rather than the large, quantified cohort studies available for several other conditions.",
    citations: [
      { source: 'IBS Symptoms in Women: Pregnancy, Female Hormones, and Menopause, IBS Self Help and Support Group', url: 'https://www.helpforibs.com/footer/pregnancy.asp' },
    ],
    overallTier: 'weak',
  },

  // -- Second depth pass, 2026-08-08, continuing the full-parity work
  // beyond the first structural pass. Every citation independently
  // verified via WebSearch.
  {
    id: 'ibs-sibo-real-connection-caveat',
    category: 'ibs',
    title: 'SIBO and IBS Overlap Substantially in Studies, But Which Breath Test Is Used Changes the Number',
    teaser: 'One study found SIBO in 72% of IBS patients versus 11% of controls, but a more rigorous test cuts that figure roughly in half, and even a positive test doesn\'t reliably predict actual symptoms.',
    summary:
      "Small intestinal bacterial overgrowth (SIBO), bacteria overgrowing in a part of the gut that should have relatively few, shows a substantial overlap with IBS, though the exact number depends heavily on which test is used. Using the lactulose breath test, research found SIBO in 72% of IBS patients versus just 11% of controls, a striking gap.\n\nUsing the glucose breath test instead, prevalence drops to a more modest 36.4-46%, still elevated but notably lower. This isn't a minor technical detail: current guidance states the lactulose test's positivity rate runs roughly 10 times higher than the glucose test specifically because lactulose isn't well absorbed in the small bowel, meaning some of what it detects is colonic fermentation, not true small-intestinal overgrowth, and current guidance has moved away from lactulose testing for this specific reason. An important caveat found in the same research: test positivity, on EITHER test, did not correlate with actual reported symptoms, direct evidence that a positive SIBO test doesn't reliably predict who's actually more symptomatic, and shouldn't be assumed to explain everything or mean treating it will necessarily resolve IBS symptoms.",
    citations: [
      { source: 'Prevalence of small intestinal bacterial overgrowth in irritable bowel syndrome (IBS): Correlating H2 or CH4 production with severity of IBS, PMC10134763', url: 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10134763/' },
    ],
    overallTier: 'moderate',
    relatedIds: ['ibs-post-infectious-mechanism'],
  },

  // -- Volumetric depth pass, 2026-08-08, continuing toward genuine
  // volumetric parity with Hashimoto's own depth, per direct instruction
  // that all 18 non-Hashimoto's conditions deserve the same fully
  // encompassing treatment, individually and in combination. Every
  // citation independently verified via WebSearch.
  {
    id: 'ibs-bile-acid-diarrhea-underdiagnosed',
    category: 'ibs',
    title: 'Bile Acid Diarrhea: An Underdiagnosed Cause of Diarrhea-Predominant IBS With a Treatable Answer',
    teaser: 'A systematic review found up to a third of people diagnosed with diarrhea-predominant IBS actually have bile acid malabsorption instead, a distinct, testable, and treatable condition most never get tested for.',
    summary: "Bile acid diarrhea (BAD), also called bile acid malabsorption, is an underdiagnosed condition hiding inside a substantial share of diarrhea-predominant IBS (IBS-D) diagnoses, covered in the Rome IV subtype research. Research finds bile acids, made by the liver to help digest fat, aren't properly reabsorbed in the small intestine in a subset of people, spilling into the colon and directly triggering diarrhea through their irritant effect on the colon lining.\n\nA systematic review of 15 studies (1,223 IBS-D patients) found roughly 10% had severe malabsorption, 32% moderate, and 26% mild, by diagnostic testing, meaning a large share of people labeled with IBS-D may actually have this distinct, separately treatable condition. Research finds diagnosis delayed by more than 5 years on average, and a UK study found only 1% of new chronic diarrhea cases were actually tested for it, despite treatment (bile acid sequestrant medications) being available and effective once correctly identified.\n\nThe gold-standard SeHCAT test remains accurate but isn't widely available everywhere; a newer, fecal bile acid stool test shows promise as a more accessible alternative. This is a concrete, worth-raising question for anyone with a diarrhea-predominant IBS diagnosis who hasn't improved on standard IBS treatment, since a distinct, testable, treatable cause may be hiding underneath the same symptoms.",
    citations: [
      { source: 'Pathophysiology and Clinical Management of Bile Acid Diarrhea, PMC9180966', url: 'https://pmc.ncbi.nlm.nih.gov/articles/PMC9180966/' },
      { source: 'Systematic review: the prevalence of idiopathic bile acid malabsorption as diagnosed by SeHCAT scanning in patients with diarrhoea-predominant IBS', url: 'https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2036.2009.04081.x' },
    ],
    overallTier: 'strong',
    relatedIds: ['ibs-rome-iv-subtypes'],
  },
  {
    id: 'ibs-cbt-brain-gut-therapy',
    category: 'ibs',
    title: 'Cognitive Behavioral Therapy Has Well-Established Evidence for IBS, Distinct From Hypnotherapy',
    teaser: 'Meta-analyses find CBT improves IBS bowel symptoms and quality of life, with a number-needed-to-treat between 3.5 and 5.5, making it a guideline-recommended option in its own right.',
    summary: "Cognitive behavioral therapy (CBT) is a distinct, well-evidenced brain-gut treatment for IBS, separate from the gut-directed hypnotherapy covered in the research, since it works through a different mechanism, addressing the anxiety response to abdominal symptoms directly rather than a hypnotic-suggestion approach. Systematic reviews and meta-analyses repeatedly confirm CBT's efficacy for IBS, with pooled results favoring improvement in bowel symptoms, quality of life, and psychological state.\n\nResearch quantifies the benefit with a number-needed-to-treat (NNT) between 3.5 and 5.5 for brain-gut psychological therapies broadly, a meaningful effect size by clinical standards. A specific approach, manual-based CBT using interoceptive exposure (deliberately confronting the fear response to physical gut sensations rather than avoiding it), has shown particularly strong results.\n\nCurrent practice guidelines recommend CBT specifically for people whose symptoms haven't responded well to lifestyle changes or standard medication. This is a legitimate, guideline-backed treatment option in its own right, not just a fallback when other treatments haven't worked, and it's worth asking about directly and by name, alongside or instead of gut-directed hypnotherapy, when discussing IBS management with a doctor or therapist.",
    citations: [
      { source: 'Efficacy of behavioural therapies for irritable bowel syndrome: a systematic review and network meta-analysis', url: 'https://www.sciencedirect.com/science/article/abs/pii/S2468125325002389' },
      { source: 'Durability and Effectiveness of Cognitive-Behavioral Therapy for Irritable Bowel Syndrome, Gastroenterology', url: 'https://www.gastrojournal.org/article/S0016-5085(19)41447-9/fulltext' },
    ],
    overallTier: 'strong',
    relatedIds: ['ibs-gut-directed-hypnotherapy'],
  },
  {
    id: 'ibs-gut-serotonin-mechanism',
    category: 'ibs',
    title: 'Roughly 90% of the Body\'s Serotonin Is Made in the Gut, and Its Dysregulation Is a Direct Piece of IBS\'s Mechanism',
    teaser: 'Specialized gut cells produce the overwhelming majority of the body\'s serotonin, directly controlling motility and gut-brain signaling, and research finds this system dysregulated in IBS itself.',
    summary: "One of the most surprising facts about IBS's underlying biology: roughly 90-95% of the body's total serotonin is made not in the brain, but in the gut, by specialized cells called enterochromaffin (EC) cells, even though these cells make up only about 1% of the gut's lining. Research finds this gut-made serotonin performs direct local jobs, regulating gut motility, coordinating digestive reflexes, and activating the vagus nerve, the same nerve covered elsewhere in the gut-brain-axis research. Current research finds gut serotonin production is directly regulated by the gut microbiome itself, through short-chain fatty acids and other microbial metabolites, tying this directly to the already-established fermentation and gut-health research.\n\nResearch finds dysregulation in this exact serotonin-signaling system a contributor to IBS, alongside other signaling molecules already implicated (bacterial byproducts, stress-related catecholamines like dopamine and norepinephrine). This gives a concrete biological reason IBS is a brain-gut condition and not \"just in someone's head,\" and it directly explains why the established treatments covered in the IBS research, from dietary changes that reshape the gut microbiome to CBT and hypnotherapy that work through brain-gut signaling, both have a physiological pathway to actually help.",
    citations: [
      { source: 'The Mechanism of Secretion and Metabolism of Gut-Derived 5-Hydroxytryptamine, PMC8347425', url: 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8347425/' },
      { source: 'Mechanosensory Signaling in Enterochromaffin Cells and 5-HT Release: Potential Implications for Gut Inflammation, PMC5165017', url: 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5165017/' },
    ],
    overallTier: 'strong',
    relatedIds: ['ibs-overview', 'gut-scfa-treg', 'mentalhealth-gut-scfa-mood-mechanism'],
  },

  // -- Volumetric depth pass batch 4, 2026-08-08, continuing toward
  // genuine volumetric parity with Hashimoto's own depth. Every citation
  // independently verified via WebSearch.
  {
    id: 'ibs-probiotic-strain-specificity',
    category: 'ibs',
    title: 'Not All Probiotics Help IBS Equally: Strain-Specific Evidence Matters More Than the Word "Probiotic" Itself',
    teaser: 'Two controlled trials validated one specific strain, Bifidobacterium infantis 35624, for IBS symptom relief, while a different probiotic combination tested in a head-to-head trial showed no significant benefit.',
    summary: "Probiotics for IBS carry strain-specific evidence: \"take a probiotic\" is far too generic a recommendation on its own, the specific strain used matters enormously. Two separate randomized controlled trials validated Bifidobacterium infantis 35624 specifically, finding efficacy at reducing IBS symptoms including bowel movement frequency, pain, and visceral hypersensitivity (the heightened gut-pain sensitivity covered in the IBS research), without an increase in adverse events.\n\nAn earlier systematic review found this specific strain performing better than other probiotic strains studied at the time. Demonstrating why strain-specificity matters rather than assuming all probiotics work the same way, a separate three-arm randomized trial testing single-strain formulations of Bifidobacterium lactis or Bacillus coagulans found no statistically significant difference from placebo.\n\nResearch on other specific combinations shows mixed but promising results too, Lactobacillus acidophilus DDS-1 combined with Bifidobacterium lactis UABla-12 improved abdominal pain severity in a controlled trial, and Lactobacillus paracasei HA-196 with Bifidobacterium longum R0175 showed symptom benefit in another. When considering a probiotic for IBS, the named strain matters far more than the broad category, someone choosing a product should look specifically for a strain with its published trial evidence (like B. Infantis 35624) rather than trusting a generic \"probiotic blend\" label alone.",
    citations: [
      { source: 'Bifidobacterium infantis 35624 and other probiotics in the management of irritable bowel syndrome: strain specificity, symptoms, and mechanisms', url: 'https://www.tandfonline.com/doi/full/10.1080/03007995.2017.1322571' },
      { source: 'Lactobacillus acidophilus DDS-1 and Bifidobacterium lactis UABla-12 Improve Abdominal Pain Severity and Symptomology in IBS, PMC7071206', url: 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7071206/' },
    ],
    overallTier: 'strong',
    relatedIds: ['ibs-gut-directed-hypnotherapy'],
  },
  {
    id: 'ibs-biopsychosocial-model',
    category: 'ibs',
    title: 'The Biopsychosocial Model Explains Why Stress Physically Changes IBS Symptoms',
    teaser: 'Research names psychosocial stress the single most widely acknowledged risk factor for IBS developing or relapsing, working through a bidirectional brain-gut pathway, not a "it\'s all in your head" dismissal.',
    summary: "The biopsychosocial model is a well-established framework, since it explains the actual mechanism behind why the CBT and gut-directed hypnotherapy covered in the IBS research work, and why stress reliably makes IBS symptoms worse without that meaning the condition itself is imaginary. Research finds genetic and environmental factors, early-life experiences, trauma, and social learning among them, directly shaping both brain and gut function, which then interact bidirectionally through the autonomic nervous system and the HPA axis (the same stress-hormone system covered elsewhere in the research).\n\nResearch names psychosocial stress the single most widely acknowledged risk factor for IBS developing in the first place, or relapsing once symptoms have improved. The underlying gut pathophysiology involves disturbed motility, visceral hypersensitivity, and altered brain-gut signaling, and research finds psychosocial stress directly affects gut microbial composition itself, both through stress-altered gut transit/secretion and through direct signaling effects on microbial gene expression, a concrete mechanistic bridge tying the broader gut-microbiome research directly to IBS specifically. Understanding this model reframes stress management not as a secondary, \"soft\" add-on to IBS treatment, but as an evidence-backed, mechanistically central piece of it, on equal footing with dietary approaches like low-FODMAP covered elsewhere in the IBS research.",
    citations: [
      { source: 'Biopsychosocial Aspects of Functional Gastrointestinal Disorders, PMC8809487', url: 'https://pmc.ncbi.nlm.nih.gov/articles/PMC8809487/' },
      { source: 'The neurobiology of irritable bowel syndrome, Molecular Psychiatry', url: 'https://www.nature.com/articles/s41380-023-01972-w' },
    ],
    overallTier: 'strong',
    relatedIds: ['ibs-cbt-brain-gut-therapy', 'ibs-gut-directed-hypnotherapy'],
  },
  {
    id: 'ibs-functional-dyspepsia-overlap',
    category: 'ibs',
    title: 'IBS and Functional Dyspepsia Overlap Far More Often Than Chance, a Common, and More Severe Combination',
    teaser: 'A meta-analysis found people with dyspepsia 8 times more likely to also have IBS, and research finds this overlap tracks with more severe symptoms and worse sleep than either condition alone.',
    summary:
      "Functional dyspepsia, chronic upper-abdominal discomfort, bloating, and early fullness without a clear structural cause, overlaps with IBS far more often than random chance would predict, a common combination with its distinct implications. A systematic review and meta-analysis found IBS present in 37% of people with dyspepsia, compared to just 7% in people without dyspepsia, a pooled odds ratio of 8 for the two conditions occurring together.\n\nPopulation-based data confirms this pattern varies by setting but stays substantial, one community survey found 27.1% of IBS patients and 42.1% of dyspepsia patients showing overlap. Research finds overlap the norm rather than the exception in clinical settings, and finds people with both conditions together experiencing more severe functional gastrointestinal symptoms and worse sleep disturbances than people with just one condition alone.\n\nSomeone already diagnosed with IBS who also experiences persistent upper-abdominal symptoms, early fullness, or discomfort unrelated to typical IBS bowel-pattern symptoms has an evidence-backed reason to raise functional dyspepsia specifically with a doctor, rather than assuming every digestive symptom must be explained by the IBS diagnosis alone.",
    citations: [
      { source: 'Overlap of Irritable Bowel Syndrome and Functional Dyspepsia in the Clinical Setting: Prevalence and Risk Factors, PMID 30368683', url: 'https://pubmed.ncbi.nlm.nih.gov/30368683/' },
      { source: 'Overlap of heartburn, functional dyspepsia, and irritable bowel syndrome in a population sample, PMID 35293084', url: 'https://pubmed.ncbi.nlm.nih.gov/35293084/' },
    ],
    overallTier: 'strong',
    relatedIds: ['ibs-vs-ibd-distinction'],
  },
  {
    id: 'ibs-fecal-microbiota-transplant-mixed',
    category: 'ibs',
    title: 'Fecal Transplant Shows Promise in IBD, But the Evidence for IBS Specifically Stays Unsettled',
    teaser: 'Individual randomized trials of fecal microbiota transplant for IBS have found conflicting results, and current guidelines don\'t recommend it.',
    summary: "This category's already-built research draws heavily on gut-microbiome science, and IBD's category covers positive fecal microbiota transplant (FMT) trial data for ulcerative colitis specifically. IBS is a different story: multiple randomized controlled trials have tested FMT for IBS, and they've produced conflicting results, some finding symptom improvement, others finding none. A pooled systematic review and meta-analysis found the overall picture still inconclusive, with unresolved variability in how the procedure itself is done (single-donor versus multi-donor stool, one dose versus repeated doses, delivery by capsule versus colonoscopy versus enema), any of which could plausibly explain why different trials land on different answers.\n\nCurrent management guidelines don't recommend FMT for IBS, citing the evidence as still too weak and inconsistent to support it as a standard treatment. This is a different evidence picture from IBD's more encouraging FMT data covered elsewhere, evidence that the same treatment idea doesn't automatically transfer cleanly from one gut condition to a different one, even when both are commonly discussed in the same breath.",
    citations: [
      { source: 'Fecal Microbiota Transplantation in Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials, International Journal of Molecular Sciences 2023, PMID 37834010', url: 'https://pmc.ncbi.nlm.nih.gov/articles/PMC10573019/' },
    ],
    overallTier: 'weak',
    relatedIds: ['ibd-fecal-microbiota-transplant', 'ibs-gut-serotonin-mechanism'],
  },
  {
    id: 'ibs-gut-directed-antidepressants',
    category: 'ibs',
    title: 'A Large Trial Found a Low-Dose Antidepressant Helps IBS, Working Through the Gut, Not Mood',
    teaser: 'The largest trial of its kind found low-dose amitriptyline, titrated up as needed, significantly beat placebo for IBS symptoms in primary care, used here for a different reason than treating depression.',
    summary: "A specific class of antidepressant, tricyclics like amitriptyline, has separate, well-documented value in IBS at doses far lower than what's used for depression, working through the gut-brain axis rather than through mood. The largest trial of its kind (ATLANTIS, 463 adults across 55 English primary-care practices) tested amitriptyline, started at a low 10mg nightly dose and titrated up to a maximum of 30mg based on response and side effects, as a second-line IBS treatment. The result: titrated low-dose amitriptyline significantly outperformed placebo across multiple measured outcomes at 6 months, with the trial's authors calling it definitive evidence of benefit.\n\nThe proposed mechanism is distinct from its antidepressant use: these medications appear to directly change how the central nervous system processes and dampens pain signals coming from the gut, addressing visceral hypersensitivity, the same documented mechanism already named in the gut-serotonin research.\n\nCommon side effects (dry mouth, drowsiness, blurred vision, difficulty urinating) affected a meaningful share of trial participants, part of why this stays a second-line option, tried after simpler dietary and lifestyle approaches, rather than a first choice, and always started at a low dose with gradual titration.",
    citations: [
      { source: 'Amitriptyline at Low-Dose and Titrated for Irritable Bowel Syndrome as Second-Line Treatment in primary care (ATLANTIS): a randomised, double-blind, placebo-controlled, phase 3 trial, The Lancet 2023, PMID 37858323', url: 'https://www.thelancet.com/article/S0140-6736(23)01523-4/fulltext' },
    ],
    overallTier: 'strong',
    relatedIds: ['ibs-gut-serotonin-mechanism', 'ibs-cbt-brain-gut-therapy'],
  },
  {
    id: 'ibs-pediatric-functional-gi-disorders',
    category: 'ibs',
    title: 'IBS Has a Distinct Diagnostic Category for Children, Common at That Age Too',
    teaser: 'A pooled systematic review found functional gut disorders affecting roughly 22% of children, with IBS one of four named subtypes under the same Rome IV framework the adult IBS research already uses.',
    summary:
      "The Rome IV subtypes research is written around adult diagnosis. Pediatric-specific Rome IV criteria exist too, and pooled data finds this common in childhood, not just adulthood: a systematic review found functional abdominal-pain disorders affecting roughly 22% of children (22.2% under age 4, 21.8% from age 4 to 18), organized into four named subtypes, irritable bowel syndrome, functional dyspepsia, functional abdominal pain, and abdominal migraine, a distinct fourth category with no direct adult equivalent in this same framework.\n\nPediatric Rome IV criteria were specifically updated to better fit how these conditions actually present in children, and current diagnostic guidance treats this the same way this category's adult red-flags research already does: a symptom-based diagnosis that doesn't require extensive testing once red-flag symptoms have been ruled out.\n\nA child with recurring, unexplained abdominal pain has a legitimate, already-established diagnostic pathway, not a condition that only starts being once someone reaches adulthood, and the same brain-gut-axis-based approaches covered in this category (CBT, gut-directed therapy) have growing pediatric-specific evidence behind them too.",
    citations: [
      { source: 'Systematic Review of Pediatric Functional Gastrointestinal Disorders (Rome IV Criteria), Journal of Clinical Medicine 2021, PMID 34768604', url: 'https://pmc.ncbi.nlm.nih.gov/articles/PMC8585107/' },
    ],
    overallTier: 'strong',
    relatedIds: ['ibs-rome-iv-subtypes', 'ibs-cbt-brain-gut-therapy'],
  },
  {
    id: 'ibs-global-prevalence-diagnostic-criteria',
    category: 'ibs',
    title: "IBS Prevalence Swings From 20% to Under 4% Depending on Where AND How You Ask",
    teaser: 'Western countries report IBS rates up to 20%, South Asia and the Middle East 7-10%, but research finds much of this gap may reflect which diagnostic criteria and survey method got used, not true biological difference.',
    summary:
      "IBS shows large reported differences by region, but this category's standard requires naming a complication most simple prevalence comparisons skip: how much of that difference is biology versus how much is measurement. A large meta-analysis pooling 395,385 people across 38 countries found a pooled IBS prevalence of 9.2% using the older Rome III diagnostic criteria, but pooling a separate set of studies using the newer, stricter Rome IV criteria found prevalence dropping to just 3.8%, a striking demonstration that the diagnostic definition used can swing the reported rate by more than double. Layered on top of that, regional data still shows a consistent pattern even within one criteria set: many Western countries report rates as high as 20%, while South Asia and the Middle East report 7-10%.\n\nThe caveat, from the research itself: these diagnostic criteria were built and validated mostly in Western populations, so some of the apparent regional gap may reflect the tool not translating cleanly across cultures and languages, not a true difference in how common IBS actually is. A lower reported IBS rate in a given country doesn't necessarily mean IBS is rarer there, it may partly reflect how the condition gets asked about and defined, an important caveat for anyone comparing their regional data against another country's.",
    citations: [
      { source: 'Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis, The Lancet Gastroenterology & Hepatology', url: 'https://www.thelancet.com/journals/langas/article/PIIS2468-1253(20)30217-X/abstract' },
      { source: 'Global prevalence of irritable bowel syndrome: time to consider factors beyond diagnostic criteria?, The Lancet Gastroenterology & Hepatology', url: 'https://www.thelancet.com/journals/langas/article/PIIS2468-1253(20)30211-9/abstract' },
    ],
    overallTier: 'moderate',
    relatedIds: ['ibs-overview'],
  },
  {
    id: 'ibs-visceral-hypersensitivity-mechanism',
    category: 'ibs',
    title: "IBS's Core Mechanism: a Gut That Feels More Than It Should",
    teaser: 'A well-established clinical finding sits underneath most of IBS: the gut itself reports pain and pressure at a lower physical threshold than in people without IBS.',
    summary:
      "Underneath many of the findings (the gut-brain axis, serotonin, the biopsychosocial model) sits one well-established physical mechanism: visceral hypersensitivity, a lower pain and pressure threshold specifically in the gut itself. Controlled testing using colorectal balloon distension (a standardized, measured way of testing gut sensation) consistently finds people with IBS reporting pain and urgency at a lower level of physical distension than people without IBS, not an imagined or exaggerated report, but a measurable difference in how the nervous system processes the same physical signal.\n\nThe proposed mechanism centers on the brain-gut axis itself: heightened, overactive processing of ordinary gut signals as they travel from the intestine through the spinal cord to the brain, with animal research directly demonstrating that gut inflammation can trigger a lasting hypersensitivity (persisting three weeks in one study) even in the non-inflamed part of the colon well after the original trigger resolves.\n\nStress adds an additional layer, triggering gut-bacteria imbalance and low-grade inflammation that can itself worsen this same hypersensitivity. This is a physical explanation for why an amount of gas or gut movement that wouldn't bother most people can be measurably more uncomfortable for someone with IBS, not a sign the discomfort is being overstated.",
    citations: [
      { source: 'The Importance of Visceral Hypersensitivity in Irritable Bowel Syndrome, Pharmaceuticals/MDPI', url: 'https://www.mdpi.com/1424-8247/16/10/1405' },
      { source: 'Visceral Hypersensitivity: Symptoms, Treatment, Causes & What it Is, Cleveland Clinic', url: 'https://my.clevelandclinic.org/health/diseases/22997-visceral-hypersensitivity' },
    ],
    overallTier: 'strong',
    relatedIds: ['ibs-gut-serotonin-mechanism', 'ibs-biopsychosocial-model'],
  },
  {
    id: 'ibs-global-symptom-pattern-by-country',
    category: 'ibs',
    title: 'Which IBS Symptom Predominates Differs by Country, an Underappreciated Pattern',
    teaser: 'A 8-country study found Mexican participants reporting constipation, Chinese participants reporting diarrhea, and Italian participants reporting bloating as their most predominant IBS symptom.',
    summary: "The subtype research (IBS-C, IBS-D, IBS-M) treats symptom pattern as an individual matter, but international data finds a country-level pattern sitting underneath individual variation too. A 8-country study found Mexican participants most often reporting constipation as their predominant symptom, Chinese participants most often reporting diarrhea, and Italian participants most often reporting bloating, a documented cultural or regional difference in which symptom dominates, not just random individual variation.\n\nEast Asian data adds detail: comparing Japan, China, and South Korea directly, overall IBS prevalence ran significantly lower in China than in the other two, and IBS-mixed (alternating symptoms) was the most common subtype across all three, again with national differences in how the remaining subtypes distributed.\n\nA separate, consistent finding across multiple countries: IBS-D (diarrhea-predominant) runs more common in men, while IBS-C (constipation-predominant) runs more common in women, a pattern that holds even as the OVERALL predominant symptom shifts by country. The dietary and treatment research (low-FODMAP, peppermint oil, fiber) applies across all IBS subtypes, but which subtype someone is actually likely to have may track with where they live and their cultural food background, not purely individual gut biology.",
    citations: [
      { source: 'Diagnosis of constipation by analysis of methane concentration (patent, citing the 2008 8-country cross-cultural IBS study)', url: 'https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/10066254' },
      { source: 'Prevalence of Irritable Bowel Syndrome in Japan, China, and South Korea: An International Cross-sectional Study, Journal of Neurogastroenterology and Motility', url: 'https://www.jnmjournal.org/journal/view.html?doi=10.5056%2Fjnm22037' },
    ],
    overallTier: 'moderate',
    relatedIds: ['ibs-rome-iv-subtypes', 'ibs-global-prevalence-diagnostic-criteria'],
  },
  {
    id: 'horizon-ibs',
    category: 'ibs',
    title: "Research Is Now Testing Whether Specific Gut Bacteria Strains Can Directly Treat the Brain-Gut Side of IBS",
    teaser: "The visceral-hypersensitivity mechanism runs through the brain-gut axis directly, and early research into \"psychobiotics,\" specific bacterial strains with a documented effect on that same axis, is testing whether they can treat it from the gut side.",
    summary:
      "The visceral-hypersensitivity research explains IBS as, in part, a problem of how the brain-gut axis processes ordinary gut signals. Psychobiotics, a specific class of probiotic bacteria strains with a documented, direct effect on that same brain-gut signaling, represent the field's current attempt to treat that mechanism from the gut side rather than only through the nervous system, extending the general probiotic-strain-specificity research into a more precisely targeted direction.\n\nSpecific Lactobacillus and Bifidobacterium strains have shown ability in laboratory and early human research to reduce neuroinflammation signals, support neurotrophic factors, and help rebalance neurotransmitter activity, all documented mechanisms connecting gut bacteria directly to brain-linked symptoms.\n\nExactly as the current research itself states: human trial evidence remains limited, with effects generally small to moderate and more consistently useful alongside other treatment than as a stand-alone option, and current evidence specifically for IBS is described directly in the research as too limited to support a strong recommendation either way. This is an active, promising research direction, not yet a proven treatment.",
    citations: [
      { source: 'Psychobiotics and the microbiota-gut-brain axis: Emerging paradigms in mental health modulation, Experimental Physiology', url: 'https://physoc.onlinelibrary.wiley.com/doi/full/10.1113/EP093301' },
    ],
    overallTier: 'weak',
    relatedIds: ['ibs-visceral-hypersensitivity-mechanism', 'ibs-probiotic-strain-specificity'],
  },
  {
    id: 'horizon-ibs-penfs',
    category: 'ibs',
    title: 'A Small Wearable Device Stimulates the Vagus Nerve Directly to Calm IBS Symptoms',
    teaser: "The brain-gut research explains IBS through the vagus nerve's role in gut-brain signaling. A small, ear-worn device now stimulates that same nerve directly, and a 4-week trial found significant improvement in pain, symptom severity, and disability.",
    summary:
      "The visceral-hypersensitivity and brain-gut-axis research names the vagus nerve as a central pathway carrying gut signals to the brain. Percutaneous electrical nerve field stimulation (PENFS, most often delivered through a small device worn behind the ear) works by directly stimulating that same nerve pathway from outside the body, a different, non-drug approach from anything else covered in this category. A study testing PENFS in adolescent girls with IBS found statistically significant improvement after just 4 weeks across three separate measures: symptom severity (IBS-SSS), pain sensitivity, and functional disability, all with strong statistical significance.\n\nA separate microbiome analysis from the same research found no major shift in overall gut bacteria diversity from the treatment, but did find patients who responded best carried a higher relative abundance of one specific bacterial genus (Blautia) beforehand, an early clue toward eventually predicting who benefits most. Current research has concentrated mostly on adolescents, and this represents a different, drug-free treatment avenue relevant for anyone whose IBS hasn't responded well to the dietary and medication options.",
    citations: [
      { source: 'Percutaneous electrical nerve field stimulation for adolescents with irritable bowel syndrome, Journal of Pediatric Gastroenterology and Nutrition, PMID 38284690', url: 'https://pubmed.ncbi.nlm.nih.gov/38284690/' },
      { source: 'PENFS vagal neuromodulation and gut microbiome effects in adolescent IBS, PMID 37448237', url: 'https://pubmed.ncbi.nlm.nih.gov/37448237/' },
    ],
    overallTier: 'moderate',
    relatedIds: ['horizon-ibs'],
  },
  {
    id: 'ibs-exercise-real-trial-evidence',
    category: 'ibs',
    title: 'A Randomized Trial Found Simply Getting More Active Reduces IBS Symptoms',
    teaser: 'A 102-patient controlled trial found that people coached to increase everyday physical activity had significantly fewer symptom flare-ups than those who kept their routine unchanged.',
    summary:
      "The CBT, hypnotherapy, and gut-directed antidepressants all work through the brain-gut axis, and research finds ordinary physical activity belongs alongside them, not as an afterthought. A randomized controlled trial of 102 IBS patients, comparing those coached by a physiotherapist to increase daily activity against a group told to keep their existing routine, found a significant improvement in the IBS Severity Scoring System for the active group, with clinically meaningful symptom worsening occurring in only 8 percent of the active group versus 23 percent of the unchanged-routine group.\n\nA separate 24-week trial of moderate aerobic exercise found the same benefit through a measurable mechanism: reduced inflammation and oxidative stress that directly tracked with symptom improvement, not just a subjective sense of feeling better. Consistent guidance across several controlled trials points to an achievable target, 12 weeks of moderate-intensity aerobic exercise, 3 to 5 days a week, 30 to 60 minutes a session, similar in shape to general activity guidance but with IBS-specific trial evidence directly behind it, not just a general wellness recommendation borrowed from elsewhere.",
    citations: [
      { source: 'Physical activity improves symptoms in irritable bowel syndrome: a randomized controlled trial, PMID 21206488', url: 'https://pubmed.ncbi.nlm.nih.gov/21206488/' },
      { source: 'Low-to-moderate intensity aerobic exercise training modulates irritable bowel syndrome through antioxidative and inflammatory mechanisms in women, PMID 29274540', url: 'https://pubmed.ncbi.nlm.nih.gov/29274540/' },
    ],
    overallTier: 'strong',
    relatedIds: ['ibs-cbt-brain-gut-therapy', 'ibs-biopsychosocial-model'],
  },
  {
    id: 'ibs-sex-hormones-women-real-data',
    category: 'ibs',
    title: 'IBS Is Diagnosed in Women at 1.5 to 2 Times the Rate of Men, and Shifts With the Cycle',
    teaser: "Research finds women diagnosed with IBS at 1.5 to 2 times the rate of men, with estrogen and progesterone directly implicated in the gut's motility and pain sensitivity.",
    summary:
      "Epidemiological data consistently finds women diagnosed with IBS at roughly 1.5 to 2 times the rate of men, with the gap widening between ages 12 and 70 before narrowing again later in life. Research points to female sex hormones as one of the strongest explanations: estrogen and progesterone both directly inhibit smooth-muscle contraction in the gut wall, and progesterone specifically modulates the colon's serotonin system, covered elsewhere in this category as directly involved in gut motility and IBS itself.\n\nMechanistic research also finds higher estrogen levels associated with increased pain sensitivity, while testosterone appears to carry a protective effect against pain perception, a plausible explanation for why the sex gap in IBS is so consistent. A practical, symptom-level pattern falls out of this too: women with IBS tend to experience constipation-predominant symptoms more often than men do, except specifically during menstruation, when ovarian hormone levels drop and symptoms often shift toward diarrhea-predominant instead. A cyclical shift in IBS symptoms tracking with the menstrual cycle isn't a coincidence or a sign of a separate problem, it's a hormonally-driven pattern documented directly in the literature.",
    citations: [
      { source: 'Gender-related differences in irritable bowel syndrome: Potential mechanisms of sex hormones, World Journal of Gastroenterology', url: 'https://www.wjgnet.com/1007-9327/full/v20/i22/6725.htm' },
    ],
    overallTier: 'strong',
    relatedIds: ['ibs-gut-serotonin-mechanism', 'ibs-pregnancy-genuinely-variable'],
  },
  {
    id: 'ibs-self-directed-food-avoidance-nutrient-risk',
    category: 'ibs',
    title: 'Self-Directed Food Avoidance, Not Just the Formal Low-FODMAP Diet, Carries a Nutrient-Intake Risk',
    teaser: "This category's low-FODMAP diet entry covers a structured elimination protocol, but research finds people with IBS often cut out far more food on their own, with a measurable nutritional cost.",
    summary:
      "The low-FODMAP diet is a structured, time-limited protocol, deliberately not the same thing as what many people with IBS actually do on their own. Research directly comparing IBS patients finds that severe, self-directed food avoidance and restriction (cutting out entire food groups indefinitely, without professional guidance) tracks with a measurably lower total caloric intake, lower protein intake, and lower intake of carbohydrates including fiber, compared to IBS patients who restrict less.\n\nThis matters because fiber and diverse carbohydrate intake are directly relevant to gut health elsewhere in the microbiome and motility research, so an unstructured, ever-narrowing diet can work against the same gut function someone is trying to protect. A separate finding: this same research connects greater self-directed restriction with worse, not better, quality-of-life scores, the opposite of what someone cutting out more food might expect.\n\nThe practical takeaway, consistent with the official AGA clinical guidance already informing this category's low-FODMAP research: dietary changes for IBS work best as a time-limited, professionally guided protocol with planned reintroduction, not an ever-expanding, permanent list of foods eliminated on one's own.",
    citations: [
      { source: 'Food Avoidance and Restriction in Irritable Bowel Syndrome: Relevance for Symptoms, Quality of Life and Nutrient Intake, Clinical Gastroenterology and Hepatology', url: 'https://www.cghjournal.org/article/S1542-3565(21)00715-1/fulltext' },
      { source: 'Nutrient Intake, Diet Quality, and Diet Diversity in Irritable Bowel Syndrome and the Impact of the Low FODMAP Diet, PMID 31029650', url: 'https://pubmed.ncbi.nlm.nih.gov/31029650/' },
    ],
    overallTier: 'strong',
    relatedIds: ['ibs-low-fodmap-diet', 'ibs-biopsychosocial-model'],
  },
  {
    id: 'ibs-bloating-distension-real-mechanism',
    category: 'ibs',
    title: 'Bloating and Visible Distension Are Different Things, and Research Finds Distinct Mechanisms Behind Each',
    teaser: "Research finds visible abdominal distension, sometimes expanding by as much as 12 cm, occurs in only about half of people who report the subjective sensation of bloating, two only partly overlapping phenomena, not one symptom with two names.",
    summary:
      "The visceral-hypersensitivity mechanism explains much of IBS's pain and discomfort, and research finds bloating specifically involves its own, more complicated picture. Objective measurement (abdominal inductance plethysmography, a device tracking actual abdominal-wall movement) confirms distension, a measurable physical expansion of the abdomen sometimes reaching 12 cm, is a distinct phenomenon from bloating, the subjective sensation of fullness or pressure. Research finds the two only correlate in roughly half of patients who report bloating, and correlate most consistently in IBS with constipation specifically, evidence that 'bloating' as commonly described covers more than one underlying process.\n\nIdentified contributing mechanisms include impaired gas handling and clearance, visceral hypersensitivity, altered gut bacteria and small intestinal bacterial overgrowth (covered elsewhere too), and abdomino-phrenic dyssynergia, a specific pattern where the diaphragm and abdominal wall muscles move in an uncoordinated way during digestion, physically pushing the belly outward. This last mechanism opened a different treatment path: a randomized, placebo-controlled trial found biofeedback specifically targeting and retraining that abdominal-wall movement pattern produced a significant reduction in distension, a mechanical fix for a mechanical problem, distinct from dietary or medication-based approaches.",
    citations: [
      { source: 'Thoracoabdominal Wall Motion–Guided Biofeedback Treatment of Abdominal Distention: A Randomized Placebo-Controlled Trial, Gastroenterology', url: 'https://www.gastrojournal.org/article/S0016-5085(24)00285-3/fulltext' },
      { source: 'Abdominal Bloating: Pathophysiology and Treatment, PMC3816178', url: 'https://pmc.ncbi.nlm.nih.gov/articles/PMC3816178/' },
    ],
    overallTier: 'strong',
    relatedIds: ['ibs-visceral-hypersensitivity-mechanism', 'ibs-sibo-real-connection-caveat', 'ibs-kiwifruit-prunes-psyllium-constipation-trial'],
  },
  {
    id: 'ibs-economic-work-productivity-burden',
    category: 'ibs',
    title: 'IBS Carries a Quantified, Multi-Billion-Dollar Economic and Work-Productivity Cost',
    teaser: "The quality-of-life research gets a direct number attached: over $30 billion spent annually in the US, with employees with IBS reporting 15% greater lost work productivity than coworkers without it.",
    summary:
      "The biopsychosocial and quality-of-life research gets a direct economic weight attached: research finds IBS costing the United States upward of $30 billion annually, not counting prescription or over-the-counter medication, spanning both direct medical costs and indirect costs from lost work and reduced productivity.\n\nA direct workplace study found employees with IBS reporting a 15 percent greater loss in work productivity from GI symptoms than coworkers without IBS, with the diarrhea-predominant subtype specifically showing significantly higher absenteeism (5.1 percent versus 2.9 percent of work time) and presenteeism (17.9 percent versus 11.3 percent, being physically present but functioning below capacity).\n\nA direct cost breakdown found indirect costs split roughly into absenteeism (45 percent), presenteeism (42 percent), and lost unpaid-labor productivity (13 percent), with research finding IBS-D patients specifically incurring nearly $2,500 more in indirect costs than matched controls. This quantified burden matters for the same reason the research on effective treatments (CBT, hypnotherapy, low-FODMAP, exercise) does, IBS is a costly condition, not a minor inconvenience, worth taking seriously both medically and in how workplaces and healthcare systems actually respond to it.",
    citations: [
      { source: 'The Socioeconomic Impact of Irritable Bowel Syndrome: An Analysis of Direct and Indirect Health Care Costs, Clinical Gastroenterology and Hepatology', url: 'https://www.cghjournal.org/article/S1542-3565(23)00076-9/fulltext' },
      { source: 'Health-related quality of life, work productivity, and indirect costs among patients with irritable bowel syndrome with diarrhea, PMID 28196491', url: 'https://pubmed.ncbi.nlm.nih.gov/28196491/' },
    ],
    overallTier: 'strong',
    relatedIds: ['ibs-biopsychosocial-model', 'ibs-rome-iv-subtypes'],
  },
  {
    id: 'ibs-post-covid-real-data',
    category: 'ibs',
    title: 'COVID-19 Joins the Growing List of Infections That Can Trigger IBS',
    teaser: "The post-infectious mechanism entry names ordinary gastroenteritis as a trigger, more recent follow-up studies find COVID-19 infection itself independently raises IBS risk, through the same established pathway.",
    summary:
      "The post-infectious IBS entry names an ordinary bout of gastroenteritis as an underappreciated trigger, and more recent research finds COVID-19 belongs in the same category, working through the same mechanism: ongoing low-grade immune activation, altered gut microbiome, and disturbed gut-brain axis regulation, covered elsewhere in this category as directly relevant to IBS.\n\nDirect research confirms people previously diagnosed with COVID-19 face an elevated risk of developing IBS compared with uninfected people, with specific incidence data finding post-COVID IBS in 2.5 to 5.3 percent of infected patients, a somewhat lower rate than the roughly 10 percent found after ordinary infectious enteritis, but an additional, distinct trigger nonetheless.\n\nAn identified specific risk factor stands out: having gastrointestinal symptoms at the actual onset of the COVID-19 infection independently predicted going on to develop a post-COVID functional gastrointestinal disorder, useful evidence for who's more likely to be affected. This growing evidence base means a new IBS diagnosis following a COVID-19 infection, even one that seemed mild or resolved without lasting symptoms otherwise, is worth mentioning directly to a doctor as a plausible trigger, not assumed to be an unrelated, coincidental new problem.",
    citations: [
      { source: 'Post-infection functional gastrointestinal disorders following coronavirus disease-19: a prospective follow-up cohort study, PMC10286442', url: 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10286442/' },
      { source: 'Lessons from irritable bowel syndrome: potential for understanding and managing post-COVID, PMC13033697', url: 'https://pmc.ncbi.nlm.nih.gov/articles/PMC13033697/' },
    ],
    overallTier: 'strong',
    relatedIds: ['ibs-post-infectious-mechanism', 'ibs-gut-serotonin-mechanism'],
  },
  {
    id: 'ibs-linaclotide-real-quantified-response-rates',
    category: 'ibs',
    title: "Linaclotide's Trial Numbers, Directly Quantified, Not Just 'It Works for Constipation'",
    teaser: "The rifaximin/linaclotide entry names the mechanism, direct trial data gives the actual, quantified numbers: a 61% complete-bowel-movement response versus 13.9% on placebo in a dedicated 26-week trial.",
    summary:
      "The medications entry names linaclotide as a subtype-targeted treatment for IBS with constipation, working through a distinct mechanism (directly changing fluid movement in the gut), and direct trial data gives this category's already-established mechanism concrete numbers. A dedicated 26-week randomized, double-blind, placebo-controlled trial found 61.0 percent of linaclotide-treated patients met the formal complete-spontaneous-bowel-movement responder criterion, versus just 13.9 percent on placebo, and 48.9 percent met the pain-responder criterion versus 22.6 percent on placebo, substantial, quantified separation from placebo on two distinct outcome measures.\n\nA separate Phase 3 trial conducted across China and other regions found a similar pattern: 60.0 percent of linaclotide patients versus 48.8 percent of placebo patients met the abdominal pain/discomfort responder criterion, and 31.7 percent versus 15.4 percent for overall IBS relief. A pooled analysis of 4 randomized controlled trials found linaclotide also reducing how long it took for symptoms to actually respond, not just whether they eventually did. These specific numbers give a concrete, evidence-based expectation to discuss directly with a doctor when considering linaclotide, rather than a vague sense that 'it might help.'",
    citations: [
      { source: 'Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety, PMID 22986437', url: 'https://pubmed.ncbi.nlm.nih.gov/22986437/' },
      { source: 'Linaclotide in irritable bowel syndrome with constipation: A Phase 3 randomized trial in China and other regions, PMID 29319191', url: 'https://pubmed.ncbi.nlm.nih.gov/29319191/' },
    ],
    overallTier: 'strong',
    relatedIds: ['ibs-medications-rifaximin-linaclotide', 'ibs-rome-iv-subtypes', 'ibs-kiwifruit-prunes-psyllium-constipation-trial'],
  },
  {
    id: 'ibs-quality-of-life-comparable-serious-conditions',
    category: 'ibs',
    title: "IBS's Measured Quality-of-Life Impact Rivals Stroke, COPD, and Chronic Kidney Disease",
    teaser: "The economic-burden entry names quantified work-productivity loss, a direct, standardized quality-of-life comparison finds IBS's everyday impact measuring as severe as several serious chronic organic diseases.",
    summary:
      "The economic-burden research already names quantified work-productivity costs, and a direct, standardized quality-of-life comparison adds an important, complementary finding: IBS's everyday impact isn't a minor inconvenience next to more visibly serious diseases, it measures as comparably severe. A study of 752 individuals meeting the Rome IV IBS criteria found a mean EQ-5D score (a standardized, widely used health-related quality-of-life measure) of 0.570, a score comparable to what's typically found in people with stroke, leg ulcers, or chronic obstructive pulmonary disease (COPD), all serious, visibly disabling chronic conditions. Separate research finds IBS lowering health-related quality of life to a degree similar to influenza or chronic kidney disease, further confirmation this isn't an isolated finding from one study alone.\n\nThe useful, practical detail: the same research names specific factors independently predicting worse quality of life within IBS itself, not just disease presence, symptom severity, psychological distress, and lower perceived social support, all identifiable, potentially addressable factors rather than a fixed, unchangeable burden. This standardized comparison matters because IBS is often, treated as a lesser medical concern than conditions with more visible or measurable organ damage, precisely the gap this category's biopsychosocial-model and fibromyalgia-overlap research already pushes back against, direct evidence the disease's lived impact deserves to be taken exactly as seriously.",
    citations: [
      { source: 'Factors associated with lower disease-specific and generic health-related quality of life in Rome IV irritable bowel syndrome, PMID 36544055', url: 'https://pubmed.ncbi.nlm.nih.gov/36544055/' },
      { source: 'Irritable bowel syndrome: Epidemiology, overlap disorders, pathophysiology and treatment, PMC10354571', url: 'https://pmc.ncbi.nlm.nih.gov/articles/PMC10354571/' },
    ],
    overallTier: 'strong',
    relatedIds: ['ibs-economic-work-productivity-burden', 'ibs-fibromyalgia-real-bidirectional'],
  },
  {
    id: 'ibs-eluxadoline-real-trial-data-gallbladder-warning',
    category: 'ibs',
    title: "An IBS-D Medication Works, but Carries a Specific Warning for Anyone Without a Gallbladder",
    teaser: "The rifaximin/linaclotide entry names two IBS medications, eluxadoline is a different third option, working through opioid receptors directly in the gut, with trial data and one specific, must-know safety caveat.",
    summary:
      "The medications entry names rifaximin and linaclotide as established IBS treatments, and eluxadoline, a mechanistically distinct medication for IBS with diarrhea, deserves direct coverage, including one specific safety detail to know before starting it. Eluxadoline works as a mixed opioid-receptor agonist and antagonist acting directly in the gut, distinct from a systemic opioid, designed to slow diarrhea without the constipation rebound often seen with other IBS-D drugs. Two large Phase 3 trials (IBS-3001 and IBS-3002, published together in the New England Journal of Medicine) found the 100mg dose achieving a significant composite response rate of 29.3 percent versus 19.0 percent on placebo in the first trial, and 32.7 percent versus 20.2 percent in the second, both statistically significant improvements over placebo at 26 weeks.\n\nThe specific safety warning: pancreatitis developed in 0.3 percent of the combined trial safety population (5 of 1,666 patients), and post-marketing analysis found this risk concentrated specifically among patients WITHOUT a gallbladder, an identifiable, checkable risk factor rather than a vague, universal caution. This efficacy data makes eluxadoline a legitimate third option alongside the rifaximin and linaclotide, but the gallbladder-specific pancreatitis warning is exactly the kind of detail worth confirming directly with a doctor before starting it, particularly for anyone who has had their gallbladder removed.",
    citations: [
      { source: 'Eluxadoline for Irritable Bowel Syndrome with Diarrhea, New England Journal of Medicine, PMID 26789872', url: 'https://pubmed.ncbi.nlm.nih.gov/26789872/' },
    ],
    overallTier: 'strong',
    relatedIds: ['ibs-medications-rifaximin-linaclotide', 'ibs-linaclotide-real-quantified-response-rates'],
  },
  {
    id: 'ibs-fermented-drinks',
    category: 'ibs',
    title: 'Fermented Drinks and Foods for IBS',
    teaser: 'A honey-sweetened tonic and a dairy-based one can both trip up IBS through the same FODMAP mechanism, from two completely different ingredients.',
    summary: "Honey, the sweetener behind most of this app's Wild-Fermented Fruit Tonic family, carries fructans, one of the FODMAP sugar groups IBS's established low-FODMAP framework flags as a common trigger, though a fully fermented batch has had more of its residual sugar consumed by the culture than a short one.\n\nDairy-based drinks (Milk Kefir, Ayran, Mango Lassi, Tarag-Style) carry lactose, a different FODMAP category entirely: both can cause the same bloating and discomfort through entirely different mechanisms. Carbonation itself is worth watching too, a bloating-prone gut doesn't always tolerate a fizzy drink well regardless of what's fermenting inside it, so a still, well-strained ferment like Beet Kvass is a gentler starting point than a bottle-conditioned soda-style tonic.",
    citations: [
      { source: 'National Center for Home Food Preservation (University of Georgia) fermentation overview', url: 'https://nchfp.uga.edu/how/can_ferment.html' },
    ],
    overallTier: 'moderate',
    relatedIds: ['recipe-ferment-beet-kvass', 'fermentmethod-dairy-free-gluten-free-survey'],
  },
  {
    id: 'ibs-circadian-motility-disruption',
    category: 'ibs',
    title: 'Night Shift Work Is Linked to Far Higher Rates of IBS-Like Symptoms',
    teaser: 'Gut motility itself follows a daily rhythm, higher during the day and quieter at night, and disrupting that rhythm through shift work tracks with a large jump in functional bowel symptoms.',
    summary: "Gut motility, both in the small intestine and colon, is naturally higher during the day and quieter at night, a pattern that suggests the digestive system is better equipped to process food during daytime hours. Disrupted circadian rhythm, from shift work or an altered sleep-wake cycle, has been linked to worse gastrointestinal motility and to conditions like IBS where irregular movement is a defining feature.\n\nAmong people working rotating or night shifts, reported rates of abdominal pain, constipation, diarrhea, and other functional bowel symptoms range from roughly 48 to 82%, and animal studies find that circadian rhythm disturbance alone produces IBS-like features (visceral hypersensitivity and a leakier gut lining) without any other intervention. The proposed pathway runs through gut microbiota dysbiosis, impaired motility, and low-grade inflammation, the same broad mechanism connecting circadian disruption to gut problems generally in this app's IBD entry, applied here to a functional rather than structural gut disorder.",
    citations: [
      { source: 'Disruption of Circadian Rhythms and Gut Motility: An Overview of Underlying Mechanisms and Associated Pathologies', url: 'https://pmc.ncbi.nlm.nih.gov/articles/PMC7147411/' },
      { source: 'Shiftwork, functional bowel symptoms, and the microbiome', url: 'https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8121053/' },
    ],
    overallTier: 'moderate',
    relatedIds: ['chrono-circadian-clock-biology', 'chrono-gut-microbiome-diurnal-rhythm', 'ibd-circadian-clock-disruption'],
  },

  // Complementary & Manual Therapies, added 2026-09-04. IBS is the
  // clearest negative result in this whole batch, and it is included for
  // exactly that reason: a topic that only ever reported the therapies
  // working would be an advertisement rather than a reference.
  {
    id: 'complementary-ibs-acupuncture',
    category: 'ibs',
    title: 'No Trial Found Acupuncture Better Than Sham for IBS Symptoms',
    teaser:
      'Not one trial comparing acupuncture against sham found it better for IBS symptoms or quality of life, and pooling them did not change that.',
    summary:
      "Acupuncture is offered widely for irritable bowel syndrome, and it has been tested well enough to give a clear answer. A Cochrane review of acupuncture for IBS found moderate certainty evidence of no important benefit over sham acupuncture, for symptom severity or for quality of life. None of the individual sham-controlled trials found acupuncture better, and combining their results did not produce a benefit either. The same review surfaced the finding that explains why acupuncture nonetheless has a reputation for helping IBS.\n\nIn trials comparing acupuncture against antispasmodic drugs rather than against sham, participants reported greater improvement with acupuncture, and those drugs themselves offer only a modest benefit in IBS. When a treatment beats an active drug but not a convincing placebo, what is being measured is largely the encounter rather than the needles. That is a meaningful distinction for someone with IBS, because it points toward what actually moves IBS symptoms.\n\nIBS symptoms respond strongly to the gut-brain axis, to stress, and to expectation, which is why psychological therapies and gut-directed hypnotherapy have better evidence in IBS than most drugs do. Someone who finds acupuncture sessions calming is getting something from them that matters. Choosing them over a dietary approach with trial evidence, or over a therapy aimed at the gut-brain connection directly, would be trading a stronger option for a weaker one.",
    citations: [
      {
        source:
          'Manheimer E, Cheng K, Wieland LS, et al. 2012: Acupuncture for treatment of irritable bowel syndrome (Cochrane Database Syst Rev 2012(5):CD005111)',
        url: 'https://pubmed.ncbi.nlm.nih.gov/22592702/',
      },
    ],
    overallTier: 'moderate',
    relatedIds: [
      'handson-acupuncture-where-it-does-nothing',
      'handson-acupuncture-chronic-pain',
      'handson-tracking-whether-it-works',
    ],
  },
];
